Wall Street is positive on Surface Oncology Inc (SURF). On average, analysts give Surface Oncology Inc a Strong Buy rating. The average price target is $15, which means analysts expect the stock to add by 132.92% over the next twelve months. That average ranking earns Surface Oncology Inc an Analyst Rating of 75, which is better than 75% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating SURF a Strong Buy today. Find out what this means to you and get the rest of the rankings on SURF!